The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts

Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts

(2010) Y-C Lee et al.   ONCOGENE

Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis

(2009) T Koreckij et al.   BRITISH JOURNAL OF CANCER

Effects of imatinib mesylate in osteoblastogenesis

(2009) Daniele Tibullo et al.   EXPERIMENTAL HEMATOLOGY

The Src Inhibitor AZD0530 Reversibly Inhibits the Formation and Activity of Human Osteoclasts

(2009) T. J. de Vries et al.   MOLECULAR CANCER RESEARCH

Platelet-Derived Growth Factor Receptor Signaling Is Not Involved in Osteogenic Differentiation of Human Mesenchymal Stem Cells

(2009) Akhilesh Kumar et al.   TISSUE ENGINEERING PART A

Inhibition of Protein Kinase c-Src as a Therapeutic Approach for Cancer and Bone Metastases

(2008) Nadia Rucci et al.   Anti-Cancer Agents in Medicinal Chemistry

Src as a therapeutic target in men with prostate cancer and bone metastases

(2008) Fred Saad   BJU INTERNATIONAL

Modulation of Src Activity by Low Molecular Weight Protein Tyrosine Phosphatase During Osteoblast Differentiation

(2008) Willian F. Zambuzzi et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

Molecular mechanisms and treatment of bone metastasis

(2008) Gregory A. Clines et al.   EXPERT REVIEWS IN MOLECULAR MEDICINE

Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia

(2008) S. Jonsson et al.   HAEMATOLOGICA

Successful vitrification of human amnion-derived mesenchymal stem cells

(2008) J. H. Moon et al.   HUMAN REPRODUCTION

Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor

(2008) N Brownlow et al.   LEUKEMIA

Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis

(2008) K Vandyke et al.   LEUKEMIA